When prostate cancer spreads and resists standard hormone-blocking drugs, treatment options become limited. A new study explored whether combining a targeted radiation drug with an immunotherapy drug could help men in this tough spot. The research involved 37 men with metastatic castration-resistant prostate cancer. The main goal was to see if the combination was safe and if it could trigger a meaningful drop in prostate-specific antigen (PSA), a protein that often rises with cancer activity.
The results were encouraging: 28 of the 37 men saw their PSA levels fall by at least half. This suggests the drug combination is active against the cancer in many of these patients. On the safety side, most side effects were mild to moderate. However, about 30% of men experienced more significant immune-related side effects, which are known risks of the immunotherapy drug pembrolizumab. These included issues like colitis and fatigue, but no life-threatening events or deaths were linked to the treatment.
It’s important to view these findings as a promising first step, not a final answer. This was a small, early-phase study without a comparison group, so we don’t know how this combo stacks up against other treatments. The researchers themselves note it might provide lasting benefit for a subset of patients, but larger, more definitive trials are needed to confirm that. The study was funded by government and pharmaceutical sources, including the makers of the drugs involved.